drugset
drugset / Trial / NCT03228186

Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer

NCT03228186 ↗

Phase 2 Terminated 40 enrolled University of Michigan Rogel Cancer Center
NaSingle-groupOpen-labelTreatment

Summary

This study is a single institution Phase II single arm trial to assess the efficacy of the combination of pevonedistat plus docetaxel in patients with previously treated advanced NSCLC (non-small cell lung cancer).

Timeline

Start
2018-03-05
Primary completion
2021-11-04
Completion
2021-11-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Docetaxel Small molecule 75 mg/m2 —
Subject Pevonedistat Small molecule 25 mg/m2 —

Indications

non-small cell lung carcinoma